미국의 육우 건강 시장 규모, 점유율 및 동향 분석 보고서 : 제품별, 유통 채널별, 부문별 예측(2025-2033년)

U.S. Beef Cattle Health Market Summary

The U.S. beef cattle health market size was estimated at USD 1.12 billion in 2024 and is projected to reach USD 2.35 billion by 2033, growing at a CAGR of 8.80% from 2025 to 2033. The market is experiencing growth driven by the rising prevalence of infectious and parasitic diseases, shrinking cattle herds prompting greater focus on animal health and productivity, and increasing investments in preventive veterinary care. Additionally, high cattle values and biosecurity concerns are accelerating the adoption of vaccines, diagnostics, and health monitoring technologies across beef operations.

Rising disease prevalence among cattle, both endemic and emerging, has become a major growth driver for the U.S. beef cattle health industry, pushing increased demand for diagnostics, vaccines, therapeutics, and preventive strategies. For example, as per the USDA report, Bovine Respiratory Disease (BRD) remains one of feedlot cattle's costliest health issues. Several studies show that reductions in mortality and morbidity from BRD improve animal welfare, affect beef supply, lower costs, and influence downstream markets for cattle, feed, and beef prices.

Another example is the re-emergence of the New World Screwworm, which threatens supply by prompting import bans (e.g., from Mexico), increasing treatment and biosecurity costs, and pushing beef prices upward. In response, cattle producers are investing more heavily in animal health infrastructure: enhanced surveillance, rapid diagnostics, new vaccines or antiparasitic drugs, and improved herd management practices. This investment is enlarging the cattle healthcare market. According to the USDA, in 2024, the U.S. accounted for almost 87% of the North American cattle healthcare market. Preventive healthcare, diagnostics, precision livestock farming, and therapeutics are all growing segments in the U.S. market. These trends also signal that producers and policymakers recognize disease prevention as economically essential to safeguard animals and ensure market stability, export access, and beef affordability.

Additionally, the rising number of FDA-approved drugs for beef cattle is driving the U.S. beef cattle health market, as it expands the range of available preventive and therapeutic options for producers. Recent approvals, such as Dectomax-CA1 for New World screwworm prevention and Pradalex for bovine respiratory disease, provide ranchers with practical tools to protect herd health, reduce mortality, and improve productivity. These approvals also encourage the adoption of biologics, pharmaceuticals, and medicated feed additives, enabling producers to manage disease more efficiently and mitigate economic losses, fueling overall market growth.

U.S. Beef Cattle Health Market Report Segmentation

This report forecasts revenue growth at the country level and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. beef cattle health market report based on product and distribution channel:

• Product Outlook (Revenue, USD Million, 2021 - 2033)
• Biologics
  • Vaccines
  • Attenuated Live Vaccines
  • Inactivated Vaccines
  • Subunit Vaccines
  • DNA Vaccines
  • Recombinant Vaccines
  • Autogenous Vaccines
  • Other Biologics
• Pharmaceuticals
  • Parasiticides
  • Anti-infectives
  • Anti-inflammatory
  • Analgesics
  • Others
• Medicated Feed Additives
• Distribution Channel Outlook (Revenue, USD Million, 2021 - 2033)
• Retail
• E-commerce
• Hospital/Clinic Pharmacy

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Segment Definitions
  • 1.2.1. Product
  • 1.2.2. Distribution Channel
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased Database
  • 1.4.2. GVR's Internal Database
  • 1.4.3. Secondary Sources
  • 1.4.4. Primary Research
• 1.5. Information/Data Analysis
  • 1.5.1. Data Analysis Models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Model 1 Analysis
  • 1.7.2. Model 2 Analysis
  • 1.7.3. Model 3 Analysis
• 1.8. List of Secondary Sources
• 1.9. List of Abbreviations
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. Market Variable Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Ancillary/Related Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Growing beef availability for domestic consumption
    • 3.2.1.2. Strong overseas demand for U.S. beef
    • 3.2.1.3. Supportive initiatives
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. Regulatory challenges
    • 3.2.2.2. Adverse environmental conditions
  • 3.2.3. Market Opportunity Analysis
  • 3.2.4. Market Challenge Analysis
• 3.3. Pricing Analysis
• 3.4. Estimated Animal Population, 2024
• 3.5. Market Analysis Tools
  • 3.5.1. Porter's Five Forces Analysis
  • 3.5.2. PESTEL by SWOT Analysis

Chapter 4. U.S. Beef Cattle Health Market: Product Estimates & Trend Analysis

• 4.1. U.S. Beef Cattle Health Market, By Product: Segment Dashboard
• 4.2. U.S. Beef Cattle Health Market, By Product Movement Analysis
• 4.3. U.S. Beef Cattle Health Market Estimates & Forecasts, by Product, 2021 to 2033 (USD Million)
• 4.4. Biologics
  • 4.4.1. Biologics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.4.1.1. Vaccines
      • 4.4.1.1.1. Vaccines Market Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 4.4.1.1.2. Attenuated Live Vaccines
        • 4.4.1.1.2.1. Attenuated Live Vaccines Market Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 4.4.1.1.3. Inactivated Vaccines
        • 4.4.1.1.3.1. Inactivated Vaccines Market Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 4.4.1.1.4. Subunit Vaccines
        • 4.4.1.1.4.1. Subunit Vaccines Market Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 4.4.1.1.5. DNA Vaccines
        • 4.4.1.1.5.1. DNA Vaccines Market Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 4.4.1.1.6. Recombinant Vaccines
        • 4.4.1.1.6.1. Recombinant Vaccines Market Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 4.4.1.1.7. Autogenous Vaccines
        • 4.4.1.1.7.1. Autogenous Vaccines Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.4.1.2. Other Biologics
      • 4.4.1.2.1. Other Biologics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.5. Pharmaceuticals
  • 4.5.1. Pharmaceuticals Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.5.1.1. Parasiticides
      • 4.5.1.1.1. Parasiticides Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.5.1.2. Anti-infectives
      • 4.5.1.2.1. Anti-infectives Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.5.1.3. Anti-inflammatory
      • 4.5.1.3.1. Anti-inflammatory Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.5.1.4. Analgesics
      • 4.5.1.4.1. Analgesics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.5.1.5. Others
      • 4.5.1.5.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.6. Medicated Feed Additives
  • 4.6.1. Medicated Feed Additives Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. U.S. Beef Cattle Health Market: By Distribution Channel Estimates & Trend Analysis

• 5.1. U.S. Beef Cattle Health Market, By Distribution Channel: Segment Dashboard
• 5.2. U.S. Beef Cattle Health Market, By Distribution Channel Movement Analysis
• 5.3. U.S. Beef Cattle Health Market Estimates & Forecasts, by Distribution Channel, 2021 to 2033 (USD Million)
• 5.4. Hospital/Clinic Pharmacy
  • 5.4.1. Hospital/Clinic Pharmacy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.5. Retail
  • 5.5.1. Retail Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.6. E-commerce
  • 5.6.1. E-commerce Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Competitive Landscape

• 6.1. Market Participant Categorization
  • 6.1.1. Market Leaders
  • 6.1.2. Emerging Players
• 6.2. Market Share/Assessment Analysis, 2024 (Heat Map Analysis)
• 6.3. Company Profiles
  • 6.3.1. Zoetis Inc.
    • 6.3.1.1. Participant's Overview
    • 6.3.1.2. Financial Performance
    • 6.3.1.3. Product/Service Benchmarking
    • 6.3.1.4. Strategic Initiatives
  • 6.3.2. Boehringer Ingelheim International GmbH
    • 6.3.2.1. Participant's Overview
    • 6.3.2.2. Financial Performance
    • 6.3.2.3. Product/Service Benchmarking
    • 6.3.2.4. Strategic Initiatives
  • 6.3.3. Merck & Co., Inc.
    • 6.3.3.1. Participant's Overview
    • 6.3.3.2. Financial Performance
    • 6.3.3.3. Product/Service Benchmarking
    • 6.3.3.4. Strategic Initiatives
  • 6.3.4. Virbac
    • 6.3.4.1. Participant's Overview
    • 6.3.4.2. Financial Performance
    • 6.3.4.3. Product/Service Benchmarking
    • 6.3.4.4. Strategic Initiatives
  • 6.3.5. Elanco
    • 6.3.5.1. Participant's Overview
    • 6.3.5.2. Financial Performance
    • 6.3.5.3. Product/Service Benchmarking
    • 6.3.5.4. Strategic Initiatives
  • 6.3.6. Vetoquinol S.A
    • 6.3.6.1. Participant's Overview
    • 6.3.6.2. Financial Performance
    • 6.3.6.3. Product/Service Benchmarking
    • 6.3.6.4. Strategic Initiatives
  • 6.3.7. Phibro Animal Health Corporation
    • 6.3.7.1. Participant's Overview
    • 6.3.7.2. Financial Performance
    • 6.3.7.3. Product/Service Benchmarking
    • 6.3.7.4. Strategic Initiatives
  • 6.3.8. Norbrook
    • 6.3.8.1. Participant's Overview
    • 6.3.8.2. Financial Performance
    • 6.3.8.3. Product/Service Benchmarking
    • 6.3.8.4. Strategic Initiatives
  • 6.3.9. Dechra Pharmaceuticals Plc
    • 6.3.9.1. Participant's Overview
    • 6.3.9.2. Financial Performance
    • 6.3.9.3. Product/Service Benchmarking
    • 6.3.9.4. Strategic Initiatives
  • 6.3.10. Bimeda, Inc
    • 6.3.10.1. Participant's Overview
    • 6.3.10.2. Financial Performance
    • 6.3.10.3. Product/Service Benchmarking
    • 6.3.10.4. Strategic Initiatives
  • 6.3.11. Cargill, Incorporated
    • 6.3.11.1. Participant's Overview
    • 6.3.11.2. Financial Performance
    • 6.3.11.3. Product/Service Benchmarking
    • 6.3.11.4. Strategic Initiatives
• 6.4. List of other key players